Usted buscó: immunised (Inglés - Maltés)

the whole herd should be immunised.
il-merħla kollha għandha titlaqqam.

only healthy animals should be immunised.
għandhom jiġu imlaqqma biss annimali f’saħħithom.

in all of the studies, the immunised pigs were compared with pigs that were castrated.
fl-istudji kollha, il-ħnieżer li ħadu li ġew immunizzati tqabblu mal-ħnieżer li ssewwew.

no special precautions are required for persons coming into contact with immunised animals.
ebda prekawzjoni speċjali ma hija meħtieġa għall-persuni li jiġu f’kuntatt mal-annimali li ġew immunizzati.

their piglets then become immunised when they drink the colostrum (first milk).
imbagħad il-qżieqeż tagħhom isiru immuni meta jixorbu l-kolostru (l-ewwel ħalib).

the specific at risk categories to be immunised are to be determined on the basis of the official recommendations.
il-kategoriji speċifiċi ta’ nies li jinsabu f’riskju u li għandhom jiġu mlaqqmin għandhom jiġu stabbiliti skont ir-rakkomandazzjonijiet uffiċjali.

up to 50% of the elderly subjects immunised with h5n1 vaccine combined with mf59c were seroprotected at six months.
sa 50% tal-individwi anzjani li tlaqqmu b’tilqima kontra h5n1 kombinata ma’ mf59c kienu seroprotetti wara sitt xhur.

85, 100) in the per protocol (fully immunised) population (40 cases).
85, 100) fil- popolazzjoni skont il - protokoll (imlaqqma b’ mod sħiħ) (40 każ).

for the reduction of clinical signs of progressive atrophic rhinitis in piglets by passive oral immunisation with colostrum from dams actively immunised with the vaccine.
għat- tnaqqis tas-sintomi kliniċi ta’ rinite atrofika progressiva fil-qżieqeż permezz ta’ immunita passiva orali li jieħdu meta jixorbu l-kolostrum ta’ ommijiet li kienu ġew imlaqqma kontra l- marda.

the vaccine can be used together with tetanus-serum from intervet for treatment of injured horses that have not been immunised against tetanus.
il-vaċċin jista jingħata ma tetanus-serum tal-intervet lil żwiemel midruba li mhumiex imlaqqma kontra t-tetnu.

this indirect or herd effect is due to a reduction in transmission of vaccine serotypes from immunised young children to the rest of the population and coincides with decreased nasopharyngeal carriage of vaccine serotypes.
dan l-effett indirett jew ‘tal- merħla’ hu minħabba tnaqqis fit-trasmissjoni tas-serotipi tat-tilqima minn tfal żgħar li kienu mlaqqma mill-bqija tal-popolazzjoni u jikkoinċidi mat-tnaqqis tal-carriage nażofarinġeali tas-serotipi tat- tilqima.

in case of accidental exposure in non-immunised subjects (including persons whose vaccination is incomplete or status unknown).
f’każ ta’ espożizzjoni aċċidentali f’persuni mhux imlaqqma (li jinkludu persuni li t-tilqima tagħhom ma tkunx kompleta jew li l-istat tagħha ma jkunx magħruf).

moreover, fully immunised boars develop metabolic characteristics typical of surgically castrated animals, including reduced concentrations of skatole, another key contributor to boar taint.
barra minn hekk, ħnieżer irġiel mlaqqma sew jiżviluppaw karateristiċi metaboliċi bħal ta’ annimali imsewwija b’mod kirurġiku, fosthom tnaqqis fil-konċentrazzjonijiet ta’ skatole, sustanza prinċipali oħra fir-riħa / togħma avversa assoċjati mal-faħal.

more than 37,816 infants were immunised with either prevenar or a control vaccine (meningococcal conjugate group c vaccine), at 2, 4,
iktar minn 37,816 tarbija ngħataw tilqima jew bi prevenar, jew b’tilqima tal-kontroll (tilqima ta’ grupp Ċ konjugat meningokokkali), wara 2, 4, 6 u 12-15-il xahar.

in sows and gilts, the vaccine induces the specific seroconversion of vaccinated animals; piglets are passively immunised by intake of colostrum and milk containing adhesin-specific antibodies.
fil-majjaliet u fil-qażqużiet, il-vaċċin jinduċi seroconversion speċifiku tal-annimali imlaqqma; id-drafeġ huma immunizzati passivament billi jieħdu il-colostrum u l-ħalib li fih adhesin-specific antibodies.

the response to serotype 6a, which is unique to prevenar 13, was assessed by demonstration of a 4-fold increase in the specific opa titer above pre- immunised levels.
ir-rispons għas-serotip 6a, li huwa uniku għal prevenar 13, kien ivvalutat mid-dimostrazzjoni ta’ żieda ta’ 4-darbiet fit-titer opa speċifiku ’l fuq mill-livelli qabel l-immunizzazzjoni.

in clinical studies when prevenar 13 was given 1 year after 23-valent pneumococcal polysaccharide vaccine the immune responses were lower for all serotypes compared to when prevenar 13 was given to subjects not previously immunised with 23-valent pneumococcal polysaccharide vaccine.
fi studji kliniċi meta prevenar 13 ingħata sena wara l-vaċċin polisakkaride pnewmokokkali ta’ 23-valenti r-rispons immuni kien aktar baxx għas-sertotipi kollha meta mqabbel ma’ meta prevenar 13 ingħata lil individwi li ma kienux preċedentement irċevew il-vaċċin polisakkaride pnewmokokkali ta’ 23-valenti.

more than 37,816 infants were immunised with either prevenar or a control vaccine (meningococcal conjugate group c vaccine), at 2, 4, 6 and 12-15 months of age.
iktar minn 37,816 tarbija ngħataw tilqima jew bi prevenar, jew b’tilqima tal-kontroll (tilqima ta’ grupp Ċ konjugat meningokokkali), wara 2, 4, 6 u 12-15-il xahar.